Novo Nordisk A/S - Share repurchase programme
Bagsværd, Denmark, 18 April 2016 - on 3 February 2016, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 14 billion to be executed during a 12-month period beginning 3 February 2016.Novo Nordisk News
ㅡㅡㅡㅡㅡㅡㅡ
21 April - The new facilities will be built on Novo Nordisk’s existing 31,000 m2 site in Chartres, which produces a range of the company’s insulin products as well as FlexPen®, the world’s most widely used insulin injection device. The products are exported to more than 40 countries all over the world. President and CEO Lars Rebien Sørensen says “Novo Nordisk has been operating in France for more than 50 years. Over the years we have built a very strong organisation in France, and our site in Chartres is today one of our most important strategic production sites. With the coming expansion we will further strengthen Chartres’ position in our global product supply organisation.”
ㅡㅡㅡㅡ